Navigation Links
Pfizer, Sanofi and Genentech Feature Prominently in the Oncology Edition of PharmaDeals' New Publication Series; Essential Deal Trends
Date:10/20/2011

OXFORD, England, October 20, 2011 /PRNewswire/ --

PharmaVentures today announced the launch of PharmaDeals®Essential Deal Trends: Oncology 2011. This new series of reports  is essential reading for everyone involved in developing and commercialising new drugs. The first report in the series focuses on oncology.

Oncology is the single most active deal making therapeutic area in the pharmaceutical and biotechnology industry. With such a high intensity of deal making, executives across the industry need the best information and insight to support their business decisions in this vital drive to make better drugs available for patients. PharmaDeals Essential Deal Trends: Oncology 2011 provides the data and insight that dealmakers need to be as effective as possible. Featuring all the key providers of therapies in the oncology field, including Pfizer, Genentech, Sanofi, Merck, GSK and others, the Essential Deal Trends series provides the most comprehensive deal trends coverage available. Other key deal intensive therapeutic areas including cardiovascular, CNS and respiratory will be published in the following months. Available in the iReport format with over 100 tables and figures in each report, you can extract data and tables for your own analysis and presentations.

Fintan Walton, Chief Executive of PharmaVentures, says, "Deal makers from large pharmaceutical companies to small biotechs tell us they need a high quality publication that helps them best understand the key players and deal trends in this and other vital areas of medicine. We are proud to be able to use our extensive data resources and analytical insight to produce this first in a series of key reports for the industry."

Note to Editors

If you wish to write an article, please contact us for any further information you require.

About the report:

Find out more http://www.pharmadeals.net/edt

Register your interest now

PharmaDeals® Essential Deal Trends is an exciting new deal trend analysis resource from PharmaVentures' experts providing crucial facts, figures and analysis for business decision support

Essential Deal Trends is published monthly addressing each key therapeutic area in turn including Oncology, Cardiovascular, Vaccines, and  CNS For high intensity deal making areas, such as Oncology, we update the report every 6 months, to ensure you can track shifts in trends as they happen. With comprehensive deal type coverage and segmentation by type, phase of development, and product type, Essential Deal Trends is a must-have resource for everyone involved in deal-making.

PharmaDeals Essential Deal Trends: Oncology
ISBN: 978-0-9568270-1-2 (electronic)

View the table of contents

About PharmaVentures

PharmaVentures (http://www.pharmaventures.com) is an international healthcare advisory group providing leadership in all aspects of deals and alliances, from strategy formulations to implementation. The company occupies a special position in the global marketplace because of our track record of successful outcomes, resulting from our unique insight into the world of deal making, our internationally recognised analytical and valuation capabilities, our own proprietary deal making database PharmaDeals® (http://www.pharmadeals.net), containing over 41,000 deal records, and our extensive business relationship network and our outstanding success in M&A transactions. Its subsidiary, PharmaTelevision (http://www.pharmatelevision.com) produces the world's first dedicated online pharmaceutical television channel.

Our Services Cover:

Valuation (for licensing, acquisitions, divestments, fund raising & expert testimonies)

Licensing (In and Out licensing)

M&A (Companies & Assets)

Strategy (commercialisation, deal strategy, due diligence, market entry)

Expert Testimony (Patent Infringement, Deal Disagreements, Taxation, Determining Damages)

Now in its 20th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.

PharmaDeals® Is a registered Trade Mark of PharmaVentures Ltd.

For further information, contact:
Lisa Holloway
Senior Direct Marketing Manager
+44-1865-332700
lisa.holloway@pharmaventures.com


'/>"/>
SOURCE PharmaVentures
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WWMR Announces Pain Clinic Physicians Most Appreciated Companies: Pfizer, Eli Lilly and Endo Pharmaceuticals
2. Lakewood-Amedex, Inc. Appoints William J. Robison, Former Executive Vice President of Pfizer, as Board Member
3. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
4. Pfizer, Merck, Roche/Genentech, GSK, J&J, BMS and More to Speak at Contracting & Outsourcing 2010
5. Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
6. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
7. Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants
8. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
9. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
10. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
11. Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global ... Directors has approved the payment of a quarterly cash dividend ... The cash dividend of $0.24 per share will be ... record as of the close of business on June 24, ... the Board of Directors and may be adjusted as business ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... focused on molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman ... Feynman, are given in two categories, one for experiment and the other for ...
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, ... new way to treat the disease. Surviving Mesothelioma has just posted an article on ... several Korean institutions based their mesothelioma study on the fact the Manumycin A, a ...
(Date:5/19/2016)... There is no saying when ... relentless pressures in pricing and lack in consumer confidence. ... though - numerous opportunities are up for grabs but ... presents four names in this sector: Portola Pharmaceuticals Inc. ... VTAE ), Anthera Pharmaceuticals Inc. (NASDAQ: ...
Breaking Biology Technology:
(Date:3/11/2016)... March 11, 2016 --> ... research report "Image Recognition Market by Technology (Pattern Recognition), ... Advertising), by Deployment Type (On-Premises and Cloud), by Industry ... published by MarketsandMarkets, the global market is expected to ... 29.98 Billion by 2020, at a CAGR of 19.1%. ...
(Date:3/10/2016)... , March 10, 2016   Unisys Corporation (NYSE: ... Border Protection (CBP) is testing its biometric identity solution ... Diego to help identify certain non-U.S. citizens leaving ... The test, designed to help determine the efficiency and accuracy ... in February and will run until May 2016. --> ...
(Date:3/9/2016)... -- Nigeria . Recently, the ... public service employees either did not exist with their ...    --> Nigeria . Recently, ... 23,000 public service employees either did not exist with ... unlawfully.    --> DERMALOG, the biometrics innovation ...
Breaking Biology News(10 mins):